GraniteShares Advisors LLC Sells 211 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

GraniteShares Advisors LLC decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,899 shares of the biopharmaceutical company’s stock after selling 211 shares during the period. GraniteShares Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $619,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in ALNY. SVB Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $27,000. Whipplewood Advisors LLC grew its position in Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. raised its stake in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 69 shares in the last quarter. Washington Trust Advisors Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 53.5% in the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 61 shares during the last quarter. Finally, Larson Financial Group LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 77.7% in the first quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 87 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ALNY shares. Piper Sandler upped their price objective on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Oppenheimer upgraded shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price target for the company in a report on Monday, August 4th. Truist Financial began coverage on Alnylam Pharmaceuticals in a report on Monday, July 21st. They set a “buy” rating and a $385.00 price objective on the stock. Needham & Company LLC boosted their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Finally, Evercore ISI increased their target price on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a research report on Thursday, September 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $439.58.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,274 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the completion of the sale, the executive vice president directly owned 50,121 shares in the company, valued at approximately $22,718,345.67. This trade represents a 4.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Colleen F. Reitan sold 18,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total value of $8,416,800.00. Following the completion of the transaction, the director directly owned 775 shares of the company’s stock, valued at approximately $362,390. This trade represents a 95.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 75,594 shares of company stock valued at $33,968,256 over the last quarter. Company insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.7%

Shares of ALNY stock opened at $446.40 on Monday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $484.21. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock has a market cap of $58.51 billion, a price-to-earnings ratio of -180.73 and a beta of 0.32. The stock has a 50-day moving average of $428.51 and a 200-day moving average of $332.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company’s revenue for the quarter was up 17.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.